Gregory M. Pastores
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Gregory M. Pastores has a total of 54 co-authors. Here are the top co-authors by number of shared publications:
- Derralynn A. Hughes
Lysosomal Storage Disorders Unit, Royal Free London NHS Foundation Trust, London, UK
3 shared publications - Ellen Crushell
Department of Paediatrics, School of Medicine, University College Dublin, Dublin, Ireland
2 shared publications Samantha Doyle
National Centre for Inherited Metabolic Disorders, Mater Misericordiae University Hospital, Dublin, Ireland
2 shared publicationsTim Lynch
2 shared publicationsAlex S Ioannidis
Sydney Eye Hospital, Sydney, Australia
1 shared publicationAmparo Chabás
Institut de Bioquímica Clínica, Barcelona
1 shared publication
Latest Publications
- 21 July 2022
- Published by Wiley
- p. 98-103
Fabry Disease
- 10 September 2021
- Published by Elsevier
- p. 636-638
Roscoe Owen Brady
- Open Access
- 1 January 2021
- Published by SAGE Publications in Therapeutic Advances in Rare Disease
- Vol. 2
IMPACT study: measuring the impact of caregiving on families and healthcare professionals of children and adults living with mucopolysaccharidoses in Ireland
Disease trajectories are often uncertain among individuals living with mucopolysaccharidoses (MPS) due to the progressive nature of the illness and the goal of care. This study investigated the impact on caregivers and care providers of children and adults living with MPS. The study used a cross-sectional design and a convenience sampling strategy which involved two sequential study components. The stage 1 quantitative component included three validated scales: the abbreviated World Health Organization Quality of Life (WHOQOL-BREF), the Paediatric Inventory for Parents (PIP) and the 14-item Resilience Scale (RS-14). The stage 2 qualitative component consisted of two focus groups with healthcare professionals (HCPs) (n = 9) working with children and adults living with MPS across three clinical sites in Ireland. Data were collected between November 2017 and July 2019. A total of 31 parents identified as caregivers participated in this study. The mean quality of life (QoL) score was 93.81, indicating a significantly high QoL. The PIP frequency total mean was 102.74 and difficulty mean 104.94. The mean score for the RS-14 was notably high, 81.42 out of a maximum of 98. The majority of the results showed high levels of concern for the future, with just under 50% finding themselves very often feeling scared that their child’s condition will deteriorate or that their child will die and finding these thoughts very difficult. The healthcare professionals’ (HCPs) perceptions were focused on the complexity of MPS, coping strategies, managing expectations and support services. The overall findings of the study reinforced the need for sustained and enhanced psychological support to ensure both families of children and adults living with MPS and the HCPs are supported in the continued delivery of quality patient care and outcomes. Subjective and objective measures from family caregivers and HCPs yield results that can decrease stress and improve psychological support. Impact of caregiving on families and healthcare professionals of children and adults living with mucopolysaccharidoses in Ireland Mucopolysaccharidoses (MPS) is a group of one of the many rare inherited metabolic disorders that come under category three of life-limiting conditions. Children born with this genetic condition show no change at birth, but effects start to show in subsequent years as it is a progressive disease. The severity of the condition varies according to the specific type, ranging from very mild symptoms to, in most cases, multisystemic, restricted growth or mental and physical disabilities. Recent developments in treatments for some forms of MPS have dramatically changed the quality of life (QoL) for patients. Other forms of treatment are currently under investigation and development. This study aimed to provide a detailed and reliable evidence base on the impact of caregiving for patients living with MPS on family caregivers and healthcare providers. Paper questionnaires were completed by the family caregivers of children and adults living with MPS. These three questionnaires focused on measuring QoL, parental stress and anxiety, and resilience among these families. Two focus group interviews were carried out with healthcare professionals working with children and adults living with MPS across three clinical sites in Ireland. A total of 31 parents completed the questionnaires in this study, indicating a significantly high QoL and notably high resilience. The majority of the parental stress results were related to concern for the future, with just half of the families finding themselves very often scared that their child’s condition will deteriorate or that their child will die and find these thoughts very difficult. The healthcare providers also spoke about the complexity of MPS, coping strategies, managing expectations and support services for the families of children and adults living with MPS. This study provided evidence for clinicians and policymakers to improve the availability of appropriate healthcare provisions for people living with MPS and their families.
- 1 January 2021
- Published by SAGE Publications in Therapeutic Advances in Rare Disease
- Vol. 2
Open AccessIMPACT study: measuring the impact of caregiving on families and healthcare professionals of children and adults living with mucopolysaccharidoses in Ireland
Disease trajectories are often uncertain among individuals living with mucopolysaccharidoses (MPS) due to the progressive nature of the illness and the goal of care. This study investigated the impact on caregivers and care providers of children and adults living with MPS. The study used a cross-sectional design and a convenience sampling strategy which involved two sequential study components. The stage 1 quantitative component included three validated scales: the abbreviated World Health Organization Quality of Life (WHOQOL-BREF), the Paediatric Inventory for Parents (PIP) and the 14-item Resilience Scale (RS-14). The stage 2 qualitative component consisted of two focus groups with healthcare professionals (HCPs) (n = 9) working with children and adults living with MPS across three clinical sites in Ireland. Data were collected between November 2017 and July 2019. A total of 31 parents identified as caregivers participated in this study. The mean quality of life (QoL) score was 93.81, indicating a significantly high QoL. The PIP frequency total mean was 102.74 and difficulty mean 104.94. The mean score for the RS-14 was notably high, 81.42 out of a maximum of 98. The majority of the results showed high levels of concern for the future, with just under 50% finding themselves very often feeling scared that their child’s condition will deteriorate or that their child will die and finding these thoughts very difficult. The healthcare professionals’ (HCPs) perceptions were focused on the complexity of MPS, coping strategies, managing expectations and support services. The overall findings of the study reinforced the need for sustained and enhanced psychological support to ensure both families of children and adults living with MPS and the HCPs are supported in the continued delivery of quality patient care and outcomes. Subjective and objective measures from family caregivers and HCPs yield results that can decrease stress and improve psychological support. Impact of caregiving on families and healthcare professionals of children and adults living with mucopolysaccharidoses in Ireland Mucopolysaccharidoses (MPS) is a group of one of the many rare inherited metabolic disorders that come under category three of life-limiting conditions. Children born with this genetic condition show no change at birth, but effects start to show in subsequent years as it is a progressive disease. The severity of the condition varies according to the specific type, ranging from very mild symptoms to, in most cases, multisystemic, restricted growth or mental and physical disabilities. Recent developments in treatments for some forms of MPS have dramatically changed the quality of life (QoL) for patients. Other forms of treatment are currently under investigation and development. This study aimed to provide a detailed and reliable evidence base on the impact of caregiving for patients living with MPS on family caregivers and healthcare providers. Paper questionnaires were completed by the family caregivers of children and adults living with MPS. These three questionnaires focused on measuring QoL, parental stress and anxiety, and resilience among these families. Two focus group interviews were carried out with healthcare professionals working with children and adults living with MPS across three clinical sites in Ireland. A total of 31 parents completed the questionnaires in this study, indicating a significantly high QoL and notably high resilience. The majority of the parental stress results were related to concern for the future, with just half of the families finding themselves very often scared that their child’s condition will deteriorate or that their child will die and find these thoughts very difficult. The healthcare providers also spoke about the complexity of MPS, coping strategies, managing expectations and support services for the families of children and adults living with MPS. This study provided evidence for clinicians and policymakers to improve the availability of appropriate healthcare provisions for people living with MPS and their families.
- Open Access
- 12 June 2019
- Published by BMJ in Archives of Disease in Childhood
- Vol. 104, A401
P627 Mitochondrial disease mimics
- 12 June 2019
- Published by BMJ in Archives of Disease in Childhood
- Vol. 104, A401
Open AccessP627 Mitochondrial disease mimics
- 1 December 2017
- Published by BMJ in Journal of Neurology, Neurosurgery & Psychiatry
- Vol. 88 (Suppl 1) , A37.4-A38
PO099 Autosomal dominant gene negative frontotemporal dementia-think sca17
SCA 17 is a rare, autosomal dominant ataxia caused by CAG/CAA repeat expansion in TBP gene. Dementia can occur. Parkinsonism, chorea, dystonia and pyramidal signs may occur. We report an Irish family with autosomal dominant partially penetrant frontal dementia with cerebellar atrophy due to SCA17. A 44-year-old doctor presented with 18–month history of behavioural problems. She slowed down, became apathetic and more irritable. One sister developed personality change at age 45 with apathy, poor memory; another sister at age 39 became dysarthric and unsteady. Her brother at age 52 laughed inappropriately, was dysarthric and unsteady. Mother age 73 had an arthritic antalgic gait. Father was jocular and disinhibited. The proband’s MRI brain showed cerebellar atrophy and FDG-PET:cerebellar hypometabolism. C9orf72 was negative and MAPT testing detected exon 9 c.726C>T variant in the proband. Subsequent testing on 9 siblings and both parents failed to show co-segregation with dementia. SCA17 testing revealed a TBP gene 43 repeat expansion in all affected siblings and in the ‘unaffected’ mother. The cognitive impairement in SCA17 is consistent with FTD. In familial FTD SCA17 should be considered if cerebellar atrophy is present. Segregation analysis is crucial. MAPT variant (c.726C>T exon 9) is a polymorphism.
- 1 December 2017
- Published by BMJ in Journal of Neurology, Neurosurgery & Psychiatry
- Vol. 88 (Suppl 1) , A37.4-A38
PO099 Autosomal dominant gene negative frontotemporal dementia-think sca17
SCA 17 is a rare, autosomal dominant ataxia caused by CAG/CAA repeat expansion in TBP gene. Dementia can occur. Parkinsonism, chorea, dystonia and pyramidal signs may occur. We report an Irish family with autosomal dominant partially penetrant frontal dementia with cerebellar atrophy due to SCA17. A 44-year-old doctor presented with 18–month history of behavioural problems. She slowed down, became apathetic and more irritable. One sister developed personality change at age 45 with apathy, poor memory; another sister at age 39 became dysarthric and unsteady. Her brother at age 52 laughed inappropriately, was dysarthric and unsteady. Mother age 73 had an arthritic antalgic gait. Father was jocular and disinhibited. The proband’s MRI brain showed cerebellar atrophy and FDG-PET:cerebellar hypometabolism. C9orf72 was negative and MAPT testing detected exon 9 c.726C>T variant in the proband. Subsequent testing on 9 siblings and both parents failed to show co-segregation with dementia. SCA17 testing revealed a TBP gene 43 repeat expansion in all affected siblings and in the ‘unaffected’ mother. The cognitive impairement in SCA17 is consistent with FTD. In familial FTD SCA17 should be considered if cerebellar atrophy is present. Segregation analysis is crucial. MAPT variant (c.726C>T exon 9) is a polymorphism.
- 1 January 2014
- Published by Elsevier
- p. 417-418
Gaucher's Disease
- Open Access
- 16 November 2012
- Published by American Society of Hematology in Blood
- Vol. 120 (21) , 1038
Eliglustat, an Investigational Oral Therapy for Gaucher Disease Type 1: Phase 2 Results After 4 Years of Treatment
Abstract 1038
- 16 November 2012
- Published by American Society of Hematology in Blood
- Vol. 120 (21) , 1038
Open AccessEliglustat, an Investigational Oral Therapy for Gaucher Disease Type 1: Phase 2 Results After 4 Years of Treatment
Abstract 1038
- 7 February 2012
- Published by BMJ in Journal of Medical Genetics
- Vol. 49 (3) , 212-220
Fabry International Prognostic Index: a predictive severity score for Anderson-Fabry disease
Background Anderson-Fabry disease (AFD) is a disorder of glycosphingolipid metabolism resulting from deficiency of α-galactosidase A and accumulation of globotriaosylceramide. Presentation is heterogeneous and, despite guidelines for initiation of therapy, there is no basis for defining subgroups that will progress more rapidly, whether treated or not. The authors of this study used clinical and pathological data recorded on 1483 patients in the Fabry Outcome Survey, a large international registry, to develop a prognostic severity score. Methods Parameters relevant to disease progression or outcome were initially selected, using variables that are readily available in clinical practice. Individual end points for renal, cardiac, neurological disease, and death were selected, and a composite end point developed. Potential prognostic variables were correlated with each end point, before multivariate analysis. Variables retaining significance were then used to construct organ specific and composite prognostic scores. Kaplan–Meier (KM) analysis, according to score, was performed for each end point. Results Analysis demonstrated that it is possible to differentiate groups of patients with different outcome probabilities. Cardiac, renal and neurological end points could each be categorised into three separate groups. The 80% event-free survival for these groups differed by approximately 10 years. The overall composite score, the Fabry International Prognostic Index (FIPI), distinguished two distinct groups where the 50% event-free survival differed by 10 years. Conclusions A prognostic scoring system for AFD has been developed and retrospective validation performed. The FIPI should prove to be a valuable tool in the counselling and management of AFD patients, and in comparative analyses of outcome using different therapies.
- 7 February 2012
- Published by BMJ in Journal of Medical Genetics
- Vol. 49 (3) , 212-220
Fabry International Prognostic Index: a predictive severity score for Anderson-Fabry disease
Background Anderson-Fabry disease (AFD) is a disorder of glycosphingolipid metabolism resulting from deficiency of α-galactosidase A and accumulation of globotriaosylceramide. Presentation is heterogeneous and, despite guidelines for initiation of therapy, there is no basis for defining subgroups that will progress more rapidly, whether treated or not. The authors of this study used clinical and pathological data recorded on 1483 patients in the Fabry Outcome Survey, a large international registry, to develop a prognostic severity score. Methods Parameters relevant to disease progression or outcome were initially selected, using variables that are readily available in clinical practice. Individual end points for renal, cardiac, neurological disease, and death were selected, and a composite end point developed. Potential prognostic variables were correlated with each end point, before multivariate analysis. Variables retaining significance were then used to construct organ specific and composite prognostic scores. Kaplan–Meier (KM) analysis, according to score, was performed for each end point. Results Analysis demonstrated that it is possible to differentiate groups of patients with different outcome probabilities. Cardiac, renal and neurological end points could each be categorised into three separate groups. The 80% event-free survival for these groups differed by approximately 10 years. The overall composite score, the Fabry International Prognostic Index (FIPI), distinguished two distinct groups where the 50% event-free survival differed by 10 years. Conclusions A prognostic scoring system for AFD has been developed and retrospective validation performed. The FIPI should prove to be a valuable tool in the counselling and management of AFD patients, and in comparative analyses of outcome using different therapies.
- 1 December 2010
- Published by Springer Nature in Wiener Medizinische Wochenschrift
- Vol. 160 (23-24) , 594-599
The pathophysiology of GD – current understanding and rationale for existing and emerging therapeutic approaches
Morbus Gaucher ist eine genetische Erkrankung des Sphingolipidstoffwechsels, die durch eine Fehlfunktion des lysosomalen membranassoziierten Glykoproteins Glucozerebrosidase hervorgerufen wird. Die Folgen sind eine intrazelluläre Speicherung von Glukosylzeramid und anderen Glukolipiden. Obwohl der Gendefekt und die relevanten biochemischen Veränderungen bei GD bekannt sind, werden alle Mechanismen, die zu den Erkrankungsmanifestationen führen, bislang noch nicht vollständig verstanden. Die progressive Zunahme von Speicherzellen erklärt zwar einige der Erkrankungsmanifestationen, jedoch die gesamte Pathologie der Erkrankung scheint von komplexerer Natur mit einem Einfluß des gespeicherten Materials auf diverse intra-und ertrazelluläre Funktionen zu sein. Im folgenden Artikel wird das Glukozerebrosidase-Gen und sein Proteinprodukt zu verschiedenen metabolischen Gesichtspunkten betrachtet und damit im Zusammenhang die aktuell verfügbaren bzw. in Entwicklung befindlichen therapeutischen Ansätze und deren Wirkungsweisen auf die pathologischen Abläufe bei GD analysiert. Gaucher disease is a genetic disorder of sphingolipid metabolism resulting from dysfunction of the lysosomal membrane-associated glycoprotein glucocerebrosidase (GBA) and resulting in intracellular accumulation of glucosylceramide and other glycolipids. Although the gene defect and relevant biochemical pathways have been defined, the mechanisms by which substrate accumulation causes disease manifestations are not well understood. The direct effects of a build up of substrate laden cells may account for some aspects of disease but the overall pathology is likely to be more complex with effects of stored material on a variety of intra and extra cellular functions. In this article we review the GBA gene and its protein product, with associated defects, lipid metabolism and storage, enzyme misfolding and endoplasmic reticulum stress, calcium homeostasis, oxidative stress and autophagy and at each point examine how therapies that are currently available, in clinical development or at earlier stages of basic research might address the pathological mechanisms.
- 1 December 2010
- Published by Springer Nature in Wiener Medizinische Wochenschrift
- Vol. 160 (23-24) , 594-599
The pathophysiology of GD – current understanding and rationale for existing and emerging therapeutic approaches
Morbus Gaucher ist eine genetische Erkrankung des Sphingolipidstoffwechsels, die durch eine Fehlfunktion des lysosomalen membranassoziierten Glykoproteins Glucozerebrosidase hervorgerufen wird. Die Folgen sind eine intrazelluläre Speicherung von Glukosylzeramid und anderen Glukolipiden. Obwohl der Gendefekt und die relevanten biochemischen Veränderungen bei GD bekannt sind, werden alle Mechanismen, die zu den Erkrankungsmanifestationen führen, bislang noch nicht vollständig verstanden. Die progressive Zunahme von Speicherzellen erklärt zwar einige der Erkrankungsmanifestationen, jedoch die gesamte Pathologie der Erkrankung scheint von komplexerer Natur mit einem Einfluß des gespeicherten Materials auf diverse intra-und ertrazelluläre Funktionen zu sein. Im folgenden Artikel wird das Glukozerebrosidase-Gen und sein Proteinprodukt zu verschiedenen metabolischen Gesichtspunkten betrachtet und damit im Zusammenhang die aktuell verfügbaren bzw. in Entwicklung befindlichen therapeutischen Ansätze und deren Wirkungsweisen auf die pathologischen Abläufe bei GD analysiert. Gaucher disease is a genetic disorder of sphingolipid metabolism resulting from dysfunction of the lysosomal membrane-associated glycoprotein glucocerebrosidase (GBA) and resulting in intracellular accumulation of glucosylceramide and other glycolipids. Although the gene defect and relevant biochemical pathways have been defined, the mechanisms by which substrate accumulation causes disease manifestations are not well understood. The direct effects of a build up of substrate laden cells may account for some aspects of disease but the overall pathology is likely to be more complex with effects of stored material on a variety of intra and extra cellular functions. In this article we review the GBA gene and its protein product, with associated defects, lipid metabolism and storage, enzyme misfolding and endoplasmic reticulum stress, calcium homeostasis, oxidative stress and autophagy and at each point examine how therapies that are currently available, in clinical development or at earlier stages of basic research might address the pathological mechanisms.
- 7 July 2006
- Published by Taylor & Francis
- p. 341-354
Enzyme Replacement Therapy for Type I Gaucher Disease
- 7 July 2006
- Published by Taylor & Francis
- p. 341-354
Enzyme Replacement Therapy for Type I Gaucher Disease